Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

CAR T cells improve patients' quality of life: a study

2.

Nasal therapeutic HPV vaccine could prevent cervical cancer

3.

'Ray of hope': New developments in the fight against various cancers.

4.

Why Encouragement May Not Improve Motivation in Depression

5.

Breast Cancer Survivors: Who Benefits From Weight-Loss Meds?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot